A Phase 2 Trial of Interferon-γ (IFN-γ) in Combination With Donor Leukocyte Infusion (DLI) to Treat Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 57
- 试验地点
- 5
- 主要终点
- Event-free survival (EFS)
研究概览
简要总结
This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort. The study will further contribute to this effort through the collection of leukemia cells pre- and post-in vivo IFN-γ therapy. As in the previously conducted phase 1 trial, this trial will assess whether leukemia blasts are responsive to IFN-γ in vitro and in vivo. Single-cell RNA sequencing (scRNAseq) will be performed to evaluate transcriptomic changes induced by IFN-γ in leukemia cell subsets, including those with stem cell characteristics.
详细描述
This novel regimen has the potential to address a significant unmet need for this high-risk population of patients who have few, if any, effective therapeutic options. In Cohort 1, if this trial confirms the clinical efficacy of IFN-γ/DLI in patients with relapsed AML/MDS after HLA-matched alloSCT, it may establish a new therapeutic approach for post-transplant AML/MDS relapse. Cohort 2 will further evaluate the safety and potential efficacy of IFN-γ/DLI in patients with relapsed AML/MDS after haploidentical alloSCT, where treatment options are also limited and the risk of GVHD requires careful assessment. Together, these cohorts would provide a rationale to explore additional indications for IFN-γ in the context of alloSCT, including 1) IFN-γ/DLI for relapsed disease after haploidentical alloSCT; 2) pre-emptive post-alloSCT treatment of patients transplanted with measurable residual disease (MRD) or with poor-risk AML/MDS, such as disease with TP53 mutations; and 3) prevention of relapse in patients who can only tolerate reduced-intensity conditioning regimens, which in most studies are associated with higher rates of post-alloSCT AML/MDS relapse than intensive conditioning regimens. Collectively, this work may allow more patients with AML/MDS to be referred for and ultimately benefit from alloSCT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Recipients of an alloSCT for AML or MDS from a minimally 8/8 HLA-matched donor (Cohort 1: HLA -matched alloSCT recipients) or recipients of a haploidentical donor SCT for AML or MDS from a minimally 4/8 HLA-matched donor (Cohort 2: Haplo-SCT recipients)
- •AML/MDS relapsed post-alloSCT with measurable residual disease defined by either of the following criteria:
- •At least 5% or more myeloblasts based on bone marrow biopsy morphology by pathologist review. Abnormal myeloblasts cannot not exceed 30% overall 36
- •At least 0.1% of abnormal myeloblasts with a leukemia-associated immunophenotype (LAIP) by multiparameter flow cytometry. The abnormal cells with LAIP should not exceed 30% of nucleated cells.
- •Recurrent or persistent cytogenetic abnormalities detectable by FISH or karyotype analysis.
- •For patients with mutant NPM1, at least 1,000 mutant transcript copies per 106 ABL or equivalent housekeeping transcripts in bone marrow by qPCR or dPCR
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2
- •A DLI is available, or the donor is available and agrees to undergo apheresis to collect lymphocytes for infusion
- •If salvage therapy for post-alloSCT relapse was received, the therapy is limited to 1 line of the following:
- •For hypomethylating agents, venetoclax, and targeted therapies (e.g., tyrosine kinase inhibitors, IDH1/IDH2 inhibitors, or FLT3 inhibitors), the last dose must be > 2 week prior to the initiation of IFN-γ
- •For cytotoxic chemotherapy agents, the last dose must be >2 weeks prior to start of treatment for the present study
- •For investigational agents, the last dose must be ≥ 4 weeks or 5 half-lives (whichever is longer) prior to the start of treatment for the present study
- •Provision of signed and dated informed consent form
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •For female subject, who is < 55 years old without hysterectomy, oophorectomy or documented menopause, willingness to use two forms of contraception including one form of highly effective contraception (i.e., long-acting reversible contraception, oral contraceptive pills) for the duration of the study
- •For male subject, willingness to use highly effective contraception methods including male condoms by male subject and one form of highly effective contraception by his female partner (i.e., long-acting reversible contraception, oral contraceptive pills) for the duration of the study
排除标准
- •Primary engraftment failure after alloSCT
- •Evidence of mixed phenotype leukemia with lymphoid differentiation (Cohort 1: HLA -matched alloSCT recipients)
- •Grade 3 or 4 aGVHD per Mount Sinai Acute GVHD International Consortium (MAGIC) at the time of planned enrollment
- •History of grade 4 aGVHD per the MAGIC criteria
- •Moderate or severe cGVHD per NIH Consensus Criteria at time of planned enrollment
- •Any systemic immunosuppressive medications taken within 2 weeks before the enrollment
- •Grade 3 or higher non-hematologic toxicity related to any prior therapy at the time of enrollment
- •A contraindication to receive IFN-γ including a known hypersensitivity to IFN-γ, E. coli derived products or any other component of the product
- •Positive pregnancy test or currently breastfeeding on Day 1 of study treatment 37
- •Active cardiac arrhythmia not controlled by medical management or current NYHA class II or higher congestive heart failure within 2 months of enrollment unless it was due to a tachyarrhythmia which is under control at the time of enrollment
- •Active ischemic heart disease not controlled with medications within 2 months of enrollment
- •Acute or chronic pulmonary disease requiring continuous oxygen treatment
- •Seizure disorder not controlled by medications within 2 months of enrollment
- •AST or ALT > 5x ULN or total bilirubin >3x ULN at time of enrollment
- •Renal function CrCl <30 mL/min at time of enrollment using modified Cockcroft-Gault formula
- •Detection of HLA loss of heterozygosity (LOH) in relapsed malignant cells. Specifically, there has been a loss of the mismatched set of HLA alleles encoded on chromosome 6 (ie uniparental disomy of chromosome 6), within 30 days prior to enrollment (Cohort 2: Haplo-SCT recipients)
研究组 & 干预措施
Cohort 1: IFN-γ + DLI (HLA-matched donor alloSCT recipient cohort)
ACTIMMUNE® (IFN-γ-1b) at a dose of 50 mcg/m^2 (All participants will receive a 4-week period of IFN-γ monotherapy with ACTIMMUNE 100 mcg 3 times a week. This dose and schedule will be continued for 4 additional weeks and then tapered to 100 mcg weekly for an additional 4 weeks)
DLI at a dose of 10^7 CD3+ cells/kg (DLI doses will be given pending clinical assessment for disease, graft versus host disease (GVHD) and peripheral blood donor chimerism the week prior to DLI. Second DLI dose is only offered to subjects with residual disease not requiring cytotoxic therapy and without GVHD)
干预措施: Donor Leukocyte Infusion (DLI) (Biological)
Cohort 2: IFN-γ + DLI (Haploidentical donor alloSCT recipient cohort)
ACTIMMUNE® (IFN-γ-1b) at a dose of 50 mcg/m^2 (All participants will receive a 4-week period of IFN-γ monotherapy with ACTIMMUNE 100 mcg 3 times a week. This dose and schedule will be continued for 4 additional weeks and then tapered to 100 mcg weekly for an additional 4 weeks) DLI at a 1st dose of 10^6 CD3+ cells/kg, 2nd dose at a dose of 10^7 CD3+ cells/kg (DLI doses will be given pending clinical assessment for disease, graft versus host disease (GVHD) and peripheral blood donor chimerism the week prior to DLI. Second DLI dose is only offered to subjects with residual disease not requiring cytotoxic therapy and without GVHD)
干预措施: Donor Leukocyte Infusion (DLI) (Biological)
Cohort 2: IFN-γ + DLI (Haploidentical donor alloSCT recipient cohort)
ACTIMMUNE® (IFN-γ-1b) at a dose of 50 mcg/m^2 (All participants will receive a 4-week period of IFN-γ monotherapy with ACTIMMUNE 100 mcg 3 times a week. This dose and schedule will be continued for 4 additional weeks and then tapered to 100 mcg weekly for an additional 4 weeks) DLI at a 1st dose of 10^6 CD3+ cells/kg, 2nd dose at a dose of 10^7 CD3+ cells/kg (DLI doses will be given pending clinical assessment for disease, graft versus host disease (GVHD) and peripheral blood donor chimerism the week prior to DLI. Second DLI dose is only offered to subjects with residual disease not requiring cytotoxic therapy and without GVHD)
干预措施: Interferon gamma-1b (Drug)
Cohort 1: IFN-γ + DLI (HLA-matched donor alloSCT recipient cohort)
ACTIMMUNE® (IFN-γ-1b) at a dose of 50 mcg/m^2 (All participants will receive a 4-week period of IFN-γ monotherapy with ACTIMMUNE 100 mcg 3 times a week. This dose and schedule will be continued for 4 additional weeks and then tapered to 100 mcg weekly for an additional 4 weeks)
DLI at a dose of 10^7 CD3+ cells/kg (DLI doses will be given pending clinical assessment for disease, graft versus host disease (GVHD) and peripheral blood donor chimerism the week prior to DLI. Second DLI dose is only offered to subjects with residual disease not requiring cytotoxic therapy and without GVHD)
干预措施: Interferon gamma-1b (Drug)
结局指标
主要结局
Event-free survival (EFS)
时间窗: At 1 year
Cohort 1: Occurrence of treatment failure, hematologic relapse from a CR (complete remission)/CRh/Cri), or death observed from start of IFN-γ treatment. Patients alive at 1 year after start of treatment will be censored on the date of last contact.
Incidence of steroid- and ruxolitinib- refractory GVHD within 12 weeks after the first dose of IFN-γ
时间窗: 12 Weeks
Cohort 2: Lack of improvement after 7 days of methylprednisolone 2 mg/kg, AND, either of the following 1. Progression of graft-vs-host disease (GVHD) compared with baseline after 10 days of ruxolitinib, based either on an objective increase in stage/grade or new organ involvement Or 2. Lack of improvement in GVHD (PR or better) compared with baseline after at least 14 days of ruxolitinib.
次要结局
- Complete Remission (CR)(At 6 months)
- Complete remission with partial hematologic recovery (CRh)(At 6 months)
- Complete remission with incomplete count recovery (CRi)(At 6 months)
- Overall survival(Up to 1 year)
- Event-free survival (EFS) - Landmark 1-year(Up to 1 year)
- Frequency and severity of adverse events (AEs)(Up to 6 months)
- Minimal residual disease (MRD)(At 6 months)
- Rate of donor chimerism(At 6 months)
- Frequency of new onset grade 3 or 4 acute graft-versus-host disease (aGVHD)(Up to 12 months)
- Rate of transfusion independence(At 1 year)
- Frequency of new onset moderate or severe chronic GVDH (cGVHD)(Up to 12 months)
研究者
Sawa Ito, MD
Assistant Professor of Medicine
University of Pittsburgh